New approach to vaccine development

The Guardian covers the development of a new generation of virus-vectored vaccines that promise to take on a number of diseases like malaria. Instead of a traditional approach using weakened virus to produce antibodies that fight disease, researchers are adding the genetic code of molecules into the DNA of the virus. That approach is believed to be more effective in supporting a strong immune response. Efficacy trials for the new approach may be mounted in Africa in three to four years, after researchers have had a chance to test a malaria vaccine. The work is being funded by the Bill and Melinda Gates Foundation, which has funneled huge sums into the science.

- read the article on vaccine research from The Guardian

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.